Recent Company News

• 03:06 AM ET Mar 11, 2026
  

  BioArctic's AB partner Eisai to present the latest findings on lecanemab at the 2026 AD/PD (SEK 320.80, 0.00)

• 02:03 AM ET Mar 09, 2026
  

  Ipsen announces it is voluntarily withdrawing Tazverik (tazemetostat) in all indications from all Ipsen markets (€160.90, 0.00)

• 09:18 AM ET Mar 04, 2026
  

  Citius Oncology announces preliminary topline Phase 1 data from study of LYMPHIR (E7777) dosing prior to commercial CAR‑T therapy in high‑risk diffuse large B‑cell lymphoma ($1.06, 0.00)

• 10:12 AM ET Feb 28, 2026
  

  Merck announces WELIREG (belzutifan) plus LENVIMA (lenvatinib) reduced the risk of disease progression or death by 30% compared to Cabozantinib in certain previously treated patients with advanced RCC ($123.82, 0.00)

• 04:34 PM ET Feb 23, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:57 AM ET Feb 24, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 08:01 PM ET Feb 20, 2026
  

  StreetAccount Sector Summary - Healthcare Weekly Recap